These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12040531)

  • 41. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Flinn IW; O'Donnell PV; Goodrich A; Vogelsang G; Abrams R; Noga S; Marcellus D; Borowitz M; Jones R; Ambinder RF
    Biol Blood Marrow Transplant; 2000; 6(6):628-32. PubMed ID: 11128813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
    Weigert O; Dreyling M; Unterhalt M; Hiddemann W; Buske C
    Curr Oncol Rep; 2006 Sep; 8(5):368-75. PubMed ID: 16901398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs.
    Derigs HG
    Cytotherapy; 2000; 2(6):445-53. PubMed ID: 12044225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
    Le Gouill S; De Guibert S; Planche L; Brice P; Dupuis J; Cartron G; Van Hoof A; Casasnovas O; Gyan E; Tilly H; Fruchart C; Deconinck E; Fitoussi O; Gastaud L; Delwail V; Gabarre J; Gressin R; Blanc M; Foussard C; Salles G;
    Haematologica; 2011 Aug; 96(8):1128-35. PubMed ID: 21486862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
    Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
    Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab maintenance versus retreatment in follicular lymphoma.
    Palla AR; Hamadani M
    Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapy of follicular lymphoma].
    Buske C; Unterhalt M; Hiddeman W
    Internist (Berl); 2007 Apr; 48(4):372-81. PubMed ID: 17287964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
    Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.
    Kasamon YL; Jones RJ; Brodsky RA; Fuchs EJ; Matsui W; Luznik L; Powell JD; Blackford AL; Goodrich A; Gocke CD; Abrams RA; Ambinder RF; Flinn IW
    Ann Oncol; 2010 Jun; 21(6):1203-1210. PubMed ID: 19880437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
    Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.
    Hicks LK; Woods A; Buckstein R; Mangel J; Pennell N; Zhang L; Imrie K; Spaner D; Cheung MC; Boudreau A; Reis M; Crump M; Berinstein NL
    Bone Marrow Transplant; 2009 May; 43(9):701-8. PubMed ID: 19029963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
    Dreyling M; Hiddemann W
    Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
    Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
    Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase.
    Oyan B; Koc Y; Kansu E
    Int J Hematol; 2005 Feb; 81(2):155-8. PubMed ID: 15765785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
    Epperla N; Fenske TS; Lazarus HM; Hamadani M
    Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo purging and relapse prevention following ASCT.
    Gisselbrecht C
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S5-9. PubMed ID: 11840154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.